Schnieders Capital Management LLC Has $6.64 Million Position in Amgen Inc. (NASDAQ:AMGN)

Schnieders Capital Management LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,068 shares of the medical research company’s stock after selling 1,745 shares during the period. Amgen accounts for 1.5% of Schnieders Capital Management LLC’s portfolio, making the stock its 17th largest position. Schnieders Capital Management LLC’s holdings in Amgen were worth $6,644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Douglas Lane & Associates LLC grew its holdings in Amgen by 2.6% during the 3rd quarter. Douglas Lane & Associates LLC now owns 15,275 shares of the medical research company’s stock worth $4,105,000 after acquiring an additional 384 shares during the period. Ziegler Capital Management LLC grew its holdings in Amgen by 3.1% during the 3rd quarter. Ziegler Capital Management LLC now owns 9,621 shares of the medical research company’s stock worth $2,586,000 after acquiring an additional 290 shares during the period. Essex LLC acquired a new stake in Amgen during the 3rd quarter worth $228,000. Fifth Third Wealth Advisors LLC acquired a new stake in Amgen during the 3rd quarter worth $238,000. Finally, Park Place Capital Corp boosted its position in shares of Amgen by 4.9% during the third quarter. Park Place Capital Corp now owns 6,953 shares of the medical research company’s stock worth $1,869,000 after purchasing an additional 326 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Raymond James assumed coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. Morgan Stanley reduced their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. The Goldman Sachs Group lifted their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $296.95.

Amgen Stock Up 0.6 %

NASDAQ:AMGN traded up $1.63 on Tuesday, hitting $273.54. 2,493,074 shares of the company’s stock were exchanged, compared to its average volume of 2,845,341. The firm has a 50-day moving average price of $276.11 and a 200-day moving average price of $281.61. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company has a market cap of $146.72 billion, a P/E ratio of 21.90, a price-to-earnings-growth ratio of 2.50 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.09 EPS. As a group, analysts expect that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.29%. Amgen’s dividend payout ratio is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.